Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. European Lung Cancer Congress 2023

Daiichi Sankyo and AstraZeneca - Addressing the unmet need in mNSCLC: Treating progression after immunochemotherapy

Antibody-drug conjugates: Future considerations

Date

30 Mar 2023

Session

Daiichi Sankyo and AstraZeneca - Addressing the unmet need in mNSCLC: Treating progression after immunochemotherapy

Presenters

Enriqueta Felip

Authors

E. Felip

Author affiliations

  • Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona/ES

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Welcome and introduction

Presenter: Maurice Perol

Session: Daiichi Sankyo and AstraZeneca - Addressing the unmet need in mNSCLC: Treating progression after immunochemotherapy

Resources:

Webcast

Antibody-drug conjugates: Current perspectives

Presenter: Antonio Passaro

Session: Daiichi Sankyo and AstraZeneca - Addressing the unmet need in mNSCLC: Treating progression after immunochemotherapy

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.